Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Nat Med. 2013 Feb 3;19(3):368–371. doi: 10.1038/nm.3078

Figure 4. Expression of NT5C2 mutations in ALL cells induces resistance to chemotherapy with 6-MP and 6-TG.

Figure 4

(a) Viability assays in CCRF-CEM and CUTLL1 T-ALL cells expressing wild type NT5C2, relapse-associated mutant NT5C2 alleles or a red fluorescent protein control (RFP), treated with increased concentrations of 6-mercaptopurine (6-MP). (b) 6-Thioguanine (6-TG) dose response cell viability curves. Data is shown as means ± s.d.